Cancer deaths among Black men and women in the United States have declined during the past decade in the United States, a new ...

Research has shown that patients who share race and ethnicity with their medical providers have better outcomes, but often ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

The FDA accepted Regeneron’s BLA resubmission for linvoseltamab in relapsed or refractory multiple myeloma, with a decision expected by July 10, 2025.

frail patients with transplant-ineligible multiple myeloma to benefit from the therapy. The measurable residual disease-negative complete response rate was 37% among patients ages 70 to 88.

Multiple myeloma (MM), which is caused by ... can insert into the cell membrane and inhibit activation of AKT1, leading to myeloma cell death 10. Perifosine might also augment the impact of ...

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that a new real-world study on melflufen (melphalan flufenamide, branded in Europe as Pepaxti) plus ...

GSK's BCMA-directed antibody-drug conjugate Blenrep reduced the risk of death by 42 ... or refractory multiple myeloma." The data reported at ASH revealed a 74% OS rate in the Blenrep plus BorDex ...

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis and multiple myeloma/bone metastases from solid tumors.

The city of Fayetteville has introduced "The One Test," which offers a more immediate assessment of a firefighter's risk of ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.